Evidence map›Paper›PMID 31870268›Full record

ArticleCurrent HIV research2020

Small Animal Models for Human Immunodeficiency Virus (HIV), Hepatitis B, and Tuberculosis: Proceedings of an NIAID Workshop.

Ramesh Akkina, Daniel L Barber, Moses T Bility, Karl-Dimiter Bissig, Benjamin J Burwitz, Katrin Eichelberg, Janice J Endsley, J Victor Garcia, Richard Hafner, Petros C Karakousis and 11 more

Abstract read
In one paragraph

Article in Current HIV research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Editorial: Host-Directed Therapies for Tuberculosis.Frontiers in cellular and infection microbiology · 2021
    Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Ramesh AkkinaDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, United States.
Daniel L BarberNational Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, Maryland, United States.
Moses T BilityDepartment of Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States.
Karl-Dimiter BissigDepartment of Pediatrics, Duke University, Durham, North Carolina, United States.
Benjamin J BurwitzVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States.
Katrin EichelbergNational Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, Maryland, United States.
Janice J EndsleyDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States.
J Victor GarciaDivision of Infectious Diseases, Center for AIDS Research, University of North Carolina at Chapel Hill, North Carolina, United States.
Richard HafnerNational Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, Maryland, United States.
Petros C KarakousisDivision of Infectious Diseases, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.
Brent E KorbaDepartment of Microbiology & Immunology, Georgetown University, Washington, DC, United States.
Rajen KoshyNational Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, Maryland, United States.
Chris LambrosNational Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, Maryland, United States.
Stephan MenneDepartment of Microbiology & Immunology, Georgetown University, Washington, DC, United States.
Eric L NuermbergerDivision of Infectious Diseases, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.
Alexander PlossDepartment of Molecular Biology, Princeton University, Princeton, New Jersey, United States.
Brendan K PodellDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, United States.
Larisa Y PoluektovaDepartment of Pharmacology and Experimental Neuroscience and Translational Mouse Model Core Facility, University of Nebraska Medical Center, Omaha, Nebraska, United States.
Brigitte E Sanders-BeerNational Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, Maryland, United States.
Selvakumar SubbianThe Public Health Research Institute Center of New Jersey Medical School, Rutgers University, Newark, New Jersey, United States.
Angela WahlDivision of Infectious Diseases, Center for AIDS Research, University of North Carolina at Chapel Hill, North Carolina, United States.

Funding

Immune Regulation in Mycobacterial InfectionsZIAAI001171 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BARBER, DANIEL · 2012 to 2025
$16.7M
C-type Lectin Receptor Pathways in the Pathogenesis of TB/HIV Co-infectionR33AI138328 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI ENDSLEY, JANICE J, GELMAN, BENJAMIN B. · 2020 to 2022
$2.3M
HIV-induced Defects in Pulmonary Macrophages Exacerbate Mycobacterium Tuberculosis Co-infectionR01HL129881 · NHLBI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI ENDSLEY, JANICE J, GELMAN, BENJAMIN B. · 2016 to 2018
$2.1M
Mentoring in Immunometabolic Dysregulation in TB and TB/HIVK24AI143447 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KARAKOUSIS, PETROS C · 2019 to 2024
$956k
NHLBI NIH HHS R01 HL129881NIAID NIH HHS HHSN272201100001GNIAID NIH HHS K24 AI143447NIAID NIH HHS R33 AI138328
6 · The paper itself

Abstract

The main advantage of animal models of infectious diseases over in vitro studies is the gain in the understanding of the complex dynamics between the immune system and the pathogen. While small animal models have practical advantages over large animal models, it is crucial to be aware of their limitations. Although the small animal model at least needs to be susceptible to the pathogen under study to obtain meaningful data, key elements of pathogenesis should also be reflected when compared to humans. Well-designed small animal models for HIV, hepatitis viruses and tuberculosis require, additionally, a thorough understanding of the similarities and differences in the immune responses between humans and small animals and should incorporate that knowledge into the goals of the study. To discuss these considerations, the NIAID hosted a workshop on 'Small Animal Models for HIV, Hepatitis B, and Tuberculosis' on May 30, 2019. Highlights of the workshop are outlined below.

Indexed as

Disease Models, AnimalAnimalsCoinfectionGuinea PigsHepatitis BHepatitis B virusHIV-1HIV InfectionsHumansMacaca mulattaMarmotaMiceMycobacterium tuberculosisNational Institute of Allergy and Infectious Diseases (U.S.)RabbitsTuberculosisAIDSanimal modelsco-infectionsHBVHIVtuberculosis.

Identifiers

PMID31870268
PMCPMC7403688

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.